Tumor-specific mutations in low-frequency genes affect their functional properties.

Area of Science:

• Neuro-oncology
• Cancer Genomics
• Molecular Biology

Background:

• Oligodendrogliomas (OD) with 1p/19q co-deletion typically involve mutations in IDH1, IDH2, CIC, FUBP1, TERT promoter, and NOTCH1.
• Tumorigenesis is often assumed to require a higher number of somatic mutations than initially observed.

Purpose of the Study:

• To investigate if genes with low-frequency mutations contribute to oligodendroglioma initiation and progression.
• To identify novel genetic targets for oligodendroglioma treatment.

Main Methods:

• Whole-genome sequencing of three anaplastic ODs with 1p/19q co-deletion.
• Targeted resequencing of 39 additional ODs to assess mutation frequency.
• Functional analysis of selected mutated genes (NTN4, MAGEH1, GDI1, XPO7, SASH3) in cell models.

Main Results:

• Whole-genome sequencing identified 55 coding mutations, including known driver mutations and novel low-frequency mutations.
• Targeted resequencing confirmed low mutation frequencies for these novel genes.
• Functional assays demonstrated that mutations in GDI1, XPO7, and SASH3 affect cell proliferation and migration, and mutations in NTN4 and MAGEH1 alter protein subcellular localization.

Conclusions:

• Low-frequency mutated genes, previously not implicated in OD, show predicted deleterious effects and functional impacts.
• These genes and their associated pathways represent potential novel therapeutic targets for oligodendroglioma.
• The study expands the understanding of oligodendroglioma pathogenesis beyond commonly mutated genes.